原发性免疫力缺乏市场－全球产业规模、份额、趋势、机会、预测：按疾病、疗法、地区和竞争对手划分，2021-2031年

全球原发性免疫力缺乏市场预计将从 2025 年的 71.2 亿美元成长到 2031 年的 106.2 亿美元，复合年增长率为 6.89%。

原发性免疫力缺乏（PIDs）涵盖多种遗传异常，这些异常会损害免疫系统，使患者极易感染疾病和自体免疫疾病。这些疾病的治疗主要依赖免疫球蛋白替代疗法、预防性抗生素和造血干细胞移植。新生儿筛检计画的广泛应用和基因检测的日益普及是推动该领域发展的关键因素，这两项倡议共同提高了诊断率，并有助于早期发现需要终身治疗性介入的患者。

然而，血浆衍生疗法的生产过程复杂且高成本，为市场扩充性带来了巨大障碍，常常导致全球供不应求。而需要治疗的新疾病变异株的快速发现，进一步加剧了这一困境。正如国际原发性免疫力缺乏患者组织在2024年指出的那样，国际免疫学会联合会已确认超过559种原发性免疫力缺乏疾病。疾病种类的日益多样化，使得治疗通讯协定的标准化更加复杂，并给本已有限的血浆资源带来了更大的压力。

市场驱动因素

政府主导的新生儿筛检计画的扩展正成为市场成长的关键催化剂，使得在严重感染疾病发生之前儘早识别危及生命的缺陷成为可能。普遍筛检通讯协定的实施显着缩短了重症联合免疫力缺乏（SCID）等疾病的诊断延迟，确保婴儿能够迅速获得包括造血干细胞移植在内的根治性治疗。这一公共卫生领域的进步正在有效缩小重点地区疾病盛行率与实际诊断率之间的差距。例如，2024年5月，澳洲免疫力缺乏基金会宣布将SCID检测纳入所有州和地区的标准新生儿血斑筛检计画。这将系统性地扩大诊断网络，从而使需要终身护理的患者群体不断增长。

同时，免疫球蛋白替代疗法的日益普及推动了市场收入的成长，这得益于全球静脉注射和皮下注射两种给药方式需求的不断增长。随着诊断率的提高，免疫力缺乏治疗中对血浆衍生疗法的依赖性日益增强，这要求生产商扩大其血浆采集和分离能力。根据 Griffols 公司于 2025 年 2 月发布的《2024 财年全年财务报告》，该公司免疫球蛋白业务成长加速，营收成长 15.3%，凸显了强劲的基础需求。这一积极趋势在主要行业参与者中通用，CSL Limited 公司报告称，其免疫球蛋白产品组合的销售额在 2024 年增长了 20%，达到 56.6 亿美元，凸显了该治疗领域巨大的经济规模。

市场挑战

血浆衍生疗法的生产需要高度复杂的製程和大量的资金投入，这成为限制全球原发性免疫力缺乏市场扩张的主要瓶颈。与传统药物不同，免疫球蛋白替代疗法依赖人类血浆这种有限的生物原料，需要严格且高成本的采集和分离过程。由于这些固有的生产限制，供应链无法快速回应全球需求的激增，导致产品反覆短缺。这些限制使得製造商无法有效扩大生产规模，儘管患者诊断率不断提高，但收入成长和市场发展却停滞不前。

该市场的脆弱性因过度依赖特定地区的原材料供应而进一步加剧。根据血浆蛋白治疗协会 (PPTA) 2024 年的数据，北美捐赠者提供的血浆占全球整体生产所需血浆供应的 63% 以上，凸显了严重的区域不平衡。这种对单一地区关键资源的过度依赖，一旦北美出现物流中断、监管变化或劳动力短缺等问题，就会对全球治疗药物供应造成不成比例的影响。因此，供应链缺乏多样性削弱了该行业确保治疗药物持续供应的能力，直接阻碍了市场的长期永续性。

市场趋势

随着居家治疗中皮下注射免疫球蛋白（SCIG）的普及，治疗模式正在发生根本性的转变，更加强调患者的自主性，并减少对医疗机构的依赖。与需要频繁就医的传统静脉注射不同，先进的皮下注射系统使患者能够在家中自行给药，显着提高了慢性疾病患者的生活品质。这一转变对儿童患者尤其重要，因为减少就医次数对于他们长期坚持治疗至关重要。例如，2024年6月，武田製药宣布加拿大卫生署已将HyQvia的适应症扩大至2至16岁的儿童。这使其成为该年龄层唯一一种允许每3至4週在家给药的皮下注射免疫球蛋白製剂。

同时，该产业正从广泛的免疫支持转向针对特定基因突变的个人化医疗。临床医生越来越多地采用标靶疗法，作用于特定的分子通路，例如与活化磷脂3-激酶Delta综合征（APDS）相关的PI3KδDelta通路，而不是仅依赖特异性替代标靶治疗。这种精准的治疗方法可以直接调节与特定基因缺陷相关的失控免疫反应，并改善罕见突变患者的临床疗效。根据Farming Group NV于2024年5月发布的2024年第一季财报，标靶治疗Joenja的销售额达到960万美元，较上一季成长21%。这主要归功于持续发现携带APDS确诊基因标记的患者。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：原发性免疫力缺乏的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 疾病特定类别（抗体缺乏症、细胞免疫力缺乏、先天免疫缺陷症、其他）
  • 治疗方法（免疫球蛋白替代疗法、抗生素疗法、干细胞/骨髓移植、基因疗法等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美原发性免疫力缺乏市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲原发性免疫力缺乏市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区原发性免疫力缺乏市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲原发性免疫力缺乏市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲原发性免疫力缺乏市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球原发性免疫力缺乏市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• CSL Behring
• Grifols
• Takeda
• Octapharma
• Sanofi
• Baxalta
• Kamada
• Sandoz
• Baxter
• Shire

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Primary Immunodeficiency Disorders Market is projected to expand from USD 7.12 Billion in 2025 to USD 10.62 Billion by 2031, registering a CAGR of 6.89%. Primary Immunodeficiency Disorders (PIDs) encompass a diverse array of hereditary genetic anomalies that compromise the immune system, leaving patients acutely vulnerable to serious infections and autoimmune conditions. Management of these disorders primarily depends on immunoglobulin replacement therapies, prophylactic antibiotic regimens, and hematopoietic stem cell transplantation. The sector's growth is fundamentally underpinned by the widespread adoption of newborn screening initiatives and the enhanced availability of genetic testing, which collectively boost diagnostic rates and facilitate the early identification of patients requiring lifelong therapeutic intervention.

Nevertheless, the market faces a substantial scalability hurdle due to the intricate and costly nature of manufacturing plasma-derived treatments, a factor that often results in global supply deficits. This strain is exacerbated by the rapid discovery of unique disease variants necessitating care. As noted by the International Patient Organisation for Primary Immunodeficiencies in 2024, the International Union of Immunological Societies classification has identified over 559 distinct types of primary immunodeficiency. This ongoing fragmentation of the disease landscape adds complexity to the standardization of treatment protocols and places further pressure on the already finite supply of essential plasma resources.

Market Driver

The broadening of government-mandated newborn screening programs serves as a pivotal catalyst for market expansion by enabling the early identification of life-threatening defects prior to the onset of severe infections. Implementing universal screening protocols drastically minimizes diagnostic delays for conditions such as severe combined immunodeficiency (SCID), ensuring infants promptly receive curative treatments like hematopoietic stem cell transplantation. This public health evolution is effectively narrowing the disparity between disease prevalence and actual diagnosis in major regions. For instance, the Immunodeficiency Foundation Australia announced in May 2024 that every Australian state and territory has successfully incorporated SCID testing into their standard newborn bloodspot screening panels, systematically enlarging the diagnostic net and, consequently, the patient population requiring lifelong care.

Simultaneously, the rising utilization of immunoglobulin replacement therapies is driving market revenue, supported by vigorous global demand for both intravenous and subcutaneous administration methods. As diagnostic rates rise, the dependence on plasma-derived therapies for managing immune deficiencies grows, necessitating that manufacturers expand their plasma collection and fractionation capacities. According to Grifols' 'Full Year Results 2024' report released in February 2025, the company's immunoglobulin division saw accelerated growth with a 15.3% increase in revenue, highlighting strong underlying demand. This positive trend is mirrored across major industry players; CSL Limited reported in 2024 that sales of their immunoglobulin portfolio rose by 20% to $5.66 billion, underscoring the significant financial magnitude of this therapeutic sector.

Market Challenge

The immense complexity and significant capital investment required for manufacturing plasma-derived therapies represent a critical bottleneck that directly constrains the expansion of the Global Primary Immunodeficiency Disorders Market. Unlike traditional pharmaceuticals, immunoglobulin replacement therapies depend on human plasma as a finite biological raw material, necessitating strict and expensive collection and fractionation procedures. This inherent rigidity in manufacturing results in a supply chain that struggles to adapt quickly to sudden spikes in global demand, leading to recurring product shortages. Such limitations hinder manufacturers from effectively scaling production volumes, thereby stalling revenue growth and market development despite increasing patient diagnosis rates.

This market vulnerability is further compounded by a heavy reliance on specific geographic regions for raw material sourcing. Data from the Plasma Protein Therapeutics Association in 2024 indicates that North American donors contributed over 63% of the global plasma supply utilized for manufacturing, revealing a severe regional imbalance. Because of this dependence on a single region for the majority of critical resources, any logistical disruptions, regulatory shifts, or labor challenges in North America disproportionately affect the global availability of therapies. Consequently, this insufficient diversification in the supply chain impairs the industry's capacity to ensure consistent treatment access, directly inhibiting the market's long-term sustainability.

Market Trends

The growing transition toward subcutaneous immunoglobulin (SCIG) for home-based care is fundamentally altering treatment paradigms by emphasizing patient autonomy and decreasing reliance on clinical settings. In contrast to traditional intravenous methods that require frequent hospital visits, advanced facilitated subcutaneous systems permit self-administration at home, greatly improving the quality of life for those with chronic conditions. This shift is especially significant for pediatric patients, for whom reducing the burden of medical appointments is essential for long-term adherence. For example, Takeda announced in June 2024 that Health Canada had expanded HyQvia's authorization to include children aged two to sixteen, making it the sole subcutaneous immune globulin infusion for this age group that supports home administration every three to four weeks.

In parallel, the industry is moving beyond broad-spectrum immune support toward personalized medicine designed for specific genetic mutations. Clinicians are increasingly utilizing targeted therapies that address unique molecular pathways-such as the PI3K delta signaling pathway involved in activated phosphoinositide 3-kinase delta syndrome (APDS)-instead of relying exclusively on non-specific replacement therapies. This precision approach directly modulates the dysregulated immune responses linked to distinct genetic defects, thereby enhancing clinical outcomes for patients with rare variants. According to Pharming Group N.V.'s 'First Quarter 2024 Financial Results' from May 2024, revenue for the targeted therapy Joenja reached $9.6 million, a 21% sequential increase attributed to the ongoing identification of patients with confirmed genetic markers for APDS.

Key Market Players

• CSL Behring
• Grifols
• Takeda
• Octapharma
• Sanofi
• Baxalta
• Kamada
• Sandoz
• Baxter
• Shire

Report Scope

In this report, the Global Primary Immunodeficiency Disorders Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Primary Immunodeficiency Disorders Market, By Disease

• Antibody Deficiency
• Cellular Immunodeficiency
• Innate Immune Disorders
• Others

Primary Immunodeficiency Disorders Market, By Treatment

• Immunoglobulin Replacement Therapy
• Antibiotic Therapy
• Stem Cell/Bone Marrow Transplantation
• Gene Therapy
• Others

Primary Immunodeficiency Disorders Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Primary Immunodeficiency Disorders Market.

Available Customizations:

Global Primary Immunodeficiency Disorders Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Primary Immunodeficiency Disorders Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Others)
  • 5.2.2. By Treatment (Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell/Bone Marrow Transplantation, Gene Therapy, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Primary Immunodeficiency Disorders Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease
  • 6.2.2. By Treatment
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Primary Immunodeficiency Disorders Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease
      • 6.3.1.2.2. By Treatment
  • 6.3.2. Canada Primary Immunodeficiency Disorders Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease
      • 6.3.2.2.2. By Treatment
  • 6.3.3. Mexico Primary Immunodeficiency Disorders Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease
      • 6.3.3.2.2. By Treatment

7. Europe Primary Immunodeficiency Disorders Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease
  • 7.2.2. By Treatment
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Primary Immunodeficiency Disorders Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease
      • 7.3.1.2.2. By Treatment
  • 7.3.2. France Primary Immunodeficiency Disorders Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease
      • 7.3.2.2.2. By Treatment
  • 7.3.3. United Kingdom Primary Immunodeficiency Disorders Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease
      • 7.3.3.2.2. By Treatment
  • 7.3.4. Italy Primary Immunodeficiency Disorders Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease
      • 7.3.4.2.2. By Treatment
  • 7.3.5. Spain Primary Immunodeficiency Disorders Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease
      • 7.3.5.2.2. By Treatment

8. Asia Pacific Primary Immunodeficiency Disorders Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease
  • 8.2.2. By Treatment
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Primary Immunodeficiency Disorders Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease
      • 8.3.1.2.2. By Treatment
  • 8.3.2. India Primary Immunodeficiency Disorders Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease
      • 8.3.2.2.2. By Treatment
  • 8.3.3. Japan Primary Immunodeficiency Disorders Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease
      • 8.3.3.2.2. By Treatment
  • 8.3.4. South Korea Primary Immunodeficiency Disorders Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease
      • 8.3.4.2.2. By Treatment
  • 8.3.5. Australia Primary Immunodeficiency Disorders Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease
      • 8.3.5.2.2. By Treatment

9. Middle East & Africa Primary Immunodeficiency Disorders Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease
  • 9.2.2. By Treatment
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Primary Immunodeficiency Disorders Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease
      • 9.3.1.2.2. By Treatment
  • 9.3.2. UAE Primary Immunodeficiency Disorders Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease
      • 9.3.2.2.2. By Treatment
  • 9.3.3. South Africa Primary Immunodeficiency Disorders Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease
      • 9.3.3.2.2. By Treatment

10. South America Primary Immunodeficiency Disorders Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease
  • 10.2.2. By Treatment
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Primary Immunodeficiency Disorders Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease
      • 10.3.1.2.2. By Treatment
  • 10.3.2. Colombia Primary Immunodeficiency Disorders Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease
      • 10.3.2.2.2. By Treatment
  • 10.3.3. Argentina Primary Immunodeficiency Disorders Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease
      • 10.3.3.2.2. By Treatment

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Primary Immunodeficiency Disorders Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. CSL Behring
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Grifols
• 15.3. Takeda
• 15.4. Octapharma
• 15.5. Sanofi
• 15.6. Baxalta
• 15.7. Kamada
• 15.8. Sandoz
• 15.9. Baxter
• 15.10. Shire

16. Strategic Recommendations

17. About Us & Disclaimer